Inhibrx Biosciences INBX
NASDAQ INBX
$96.99 -0.94 (-0.96%)
At close: Oct 2, 2026 · 4:00 PM EDT

Inhibrx Biosciences (INBX) Cash & Equivalents (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) posted Cash & Equivalents of $133.34 million for Q2 2026, down 28.5% from $186.6 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) Cash & Equivalents (2023 - 2026) Analysis & Trends

At the end of FY2025, Inhibrx Biosciences' Cash & Equivalents came in at $124.22 million, down 18.6% from FY2024.

  • In prior years, Inhibrx Biosciences' Cash & Equivalents was $152.6 million in FY2024 (-45.1%) and $277.92 million in FY2023.
  • Quarterly Cash & Equivalents has run from a low of $124.22 million in Q4 2025 to a high of $277.92 million in Q4 2023 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 20.42 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 6.57 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 6.85 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 4.89 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 3.18 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 976.00 Mn
10 Inhibrx Biosciences 1.43 Bn 1.43 Bn - 133.34 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 133.34 Mn
Dec 31, 2025 124.22 Mn
Sep 30, 2025 153.10 Mn
Jun 30, 2025 186.60 Mn
Mar 31, 2025 216.52 Mn
Dec 31, 2024 152.60 Mn
Sep 30, 2024 196.33 Mn
Jun 30, 2024 226.90 Mn
Dec 31, 2023 277.92 Mn
API Access

Inhibrx Biosciences Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=INBX&period=max&api_key=YOUR_API_KEY